Review



atl iii  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress atl iii
    Atl Iii, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atl iii/product/MedChemExpress
    Average 93 stars, based on 4 article reviews
    atl iii - by Bioz Stars, 2026-06
    93/100 stars

    Images



    Similar Products

    atl iii  (MedChemExpress)
    93
    MedChemExpress atl iii
    Atl Iii, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atl iii/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    atl iii - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    atl iii  (AbMole Bioscience)
    90
    AbMole Bioscience atl iii
    <t>ATL</t> <t>III</t> attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .
    Atl Iii, supplied by AbMole Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atl iii/product/AbMole Bioscience
    Average 90 stars, based on 1 article reviews
    atl iii - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    atl iii  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc atl iii
    <t>ATL</t> <t>III</t> attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .
    Atl Iii, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atl iii/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    atl iii - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    atl-iii  (FUJIFILM)
    90
    FUJIFILM atl-iii
    <t>ATL</t> <t>III</t> attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .
    Atl Iii, supplied by FUJIFILM, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atl-iii/product/FUJIFILM
    Average 90 stars, based on 1 article reviews
    atl-iii - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    atl mark iii  (Acuson Corporation)
    90
    Acuson Corporation atl mark iii
    <t>ATL</t> <t>III</t> attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .
    Atl Mark Iii, supplied by Acuson Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/atl mark iii/product/Acuson Corporation
    Average 90 stars, based on 1 article reviews
    atl mark iii - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ATL III attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .

    Journal: Heliyon

    Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

    doi: 10.1016/j.heliyon.2023.e21224

    Figure Lengend Snippet: ATL III attenuates esophageal injury in RE rats A) Images show the esophagus of rats after RE establishment and ATL III treatment in samples of a) sham group, b) RE group, c) ATL III (0.6 mg/kg), d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. B) H&E stained images of the sectioned esophagus tissues of rats after RE establishment and ATL III treatment. a) sham group, b) RE group, c) ATL III (0.6 mg/kg) d) ATL-III 1.2 mg/kg, and e) ATL III 2.4 mg/kg treated groups. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after RE establishment and ATL III treatment. D) The graph indicates the gastric pH changes after RE establishment and ATL III treatment. *** indicates P < 0.001 vs. RE group. E) The graphs present the ROS and F) TBARS levels after various treatments of ATL-III group. *** indicates P < 0.001 vs. RE group .

    Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

    Techniques: Staining, Marker

    ATL III attenuates esophageal inflammation in RE rats. The graphs show the levels of various inflammatory indicators, A) IL-1β, B) IL-6, C) IL-8, and D) TNF-α. E) The Western blot analysis indicates the expression levels of various IL-1β, IL-6, IL-8, and TNF-α proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. * indicates P < 0.05 vs. RE group, and *** represents P < 0.001.

    Journal: Heliyon

    Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

    doi: 10.1016/j.heliyon.2023.e21224

    Figure Lengend Snippet: ATL III attenuates esophageal inflammation in RE rats. The graphs show the levels of various inflammatory indicators, A) IL-1β, B) IL-6, C) IL-8, and D) TNF-α. E) The Western blot analysis indicates the expression levels of various IL-1β, IL-6, IL-8, and TNF-α proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. * indicates P < 0.05 vs. RE group, and *** represents P < 0.001.

    Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

    Techniques: Western Blot, Expressing

    ATL III inhibits PI3K/AKT/NF-κB/iNOS pathway. A) Images show the esophagus of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg of ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. B) H&E stained images of the sectioned esophagus tissues of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. D) The graph signifies the gastric content pH after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. E) The image shows the ROS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. F) The image shows the TBARS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. G) The image shows the expression levels of various inflammatory indicators (TNF-α, IL-8, IL-6, and IL-1β) after treatment with ATL III + 10 mg/kg of 740 Y–P in RE rats. ** indicates P < 0.01 and *** represents P < 0.001 vs. RE. & presents P < 0.05 and &&& signifies P < 0.001 vs. RE + 2.4 mg/kg ATL III.

    Journal: Heliyon

    Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

    doi: 10.1016/j.heliyon.2023.e21224

    Figure Lengend Snippet: ATL III inhibits PI3K/AKT/NF-κB/iNOS pathway. A) Images show the esophagus of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg of ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. B) H&E stained images of the sectioned esophagus tissues of rats after treatment with a) sham group, b) RE group, c) RE+2.4 mg/kg ATL III, d) RE+2.4 mg/kg of ATL III +10 mg/kg of 740 Y–P. Arrow marker: lymphocyte infiltration. C) The graph represents the esophageal mucosal injury score after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. D) The graph signifies the gastric content pH after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. E) The image shows the ROS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. F) The image shows the TBARS levels after treatment with ATL III +10 mg/kg of 740 Y–P in RE rats. G) The image shows the expression levels of various inflammatory indicators (TNF-α, IL-8, IL-6, and IL-1β) after treatment with ATL III + 10 mg/kg of 740 Y–P in RE rats. ** indicates P < 0.01 and *** represents P < 0.001 vs. RE. & presents P < 0.05 and &&& signifies P < 0.001 vs. RE + 2.4 mg/kg ATL III.

    Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

    Techniques: Staining, Marker, Expressing

    A)ATL III inhibits PI3K/AKT/NF-κB in the esophageal tissues of RE rats. The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. B) The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard after treated with the ATL III +740 Y–P.

    Journal: Heliyon

    Article Title: Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats

    doi: 10.1016/j.heliyon.2023.e21224

    Figure Lengend Snippet: A)ATL III inhibits PI3K/AKT/NF-κB in the esophageal tissues of RE rats. The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard at the 2.4 mg/kg dose of ATL III. B) The Western blot analysis indicates the expression levels of various p-PI3K, p -AKT, iNOS, and nuclear NF-κB and Laminin B1 proteins against β-Actin as internal standard after treated with the ATL III +740 Y–P.

    Article Snippet: ATL III and 740 Y–P were obtained from Abmole Bioscience Inc. (Shanghai, China).

    Techniques: Western Blot, Expressing